For the quarter ending 2026-03-31, BCAX had $226,777K increase in cash & cash equivalents over the period. -$37,568K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -56,211 | -37,386 | -36,330 | -64,234 |
| Stock-based compensation | 5,858 | 4,449 | 3,614 | 6,943 |
| Depreciation | 44 | 43 | 24 | 38 |
| Non-cash lease expense | 273 | 297 | 249 | 349 |
| Net amortization of premiums and discounts on marketable securities | -338 | -269 | -32 | - |
| Prepaid expenses and other assets | -2,089 | -839 | 301 | -4,743 |
| Accounts payable and accrued expenses-Nonrelated Party | 11,725 | 6,423 | 3,949 | -2,715 |
| Accounts payable and accrued expenses-Related Party | -1,354 | 1,472 | -168 | 1,499 |
| Operating lease liabilities | -270 | -292 | -317 | -323 |
| Net cash used in operating activities | -37,508 | -23,886 | -29,248 | -53,700 |
| Proceeds from sale of property and equipment | - | 0 | 0 | 0 |
| Purchases of marketable securities | - | 82,094 | 236,079 | - |
| Proceeds from maturities and sales of marketable securities | 101,000 | - | - | - |
| Purchase of property and equipment | 60 | 238 | 42 | 0 |
| Net cash provided by investing activities | 100,940 | -82,332 | -236,121 | 0 |
| Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs | 161,763 | 29,498 | 0 | - |
| Proceeds from exercise of options | 1,582 | 1,732 | 436 | 595 |
| Payment for deferred offering costs | - | - | - | 0 |
| Net cash provided by financing activities | 163,345 | 31,230 | 436 | 595 |
| Net (decrease)/increase in cash and cash equivalents | 226,777 | -74,988 | -264,933 | -53,105 |
| Cash and cash equivalents at beginning of period | 96,685 | 171,673 | 489,711 | - |
| Cash and cash equivalents at end of period | 323,462 | 96,685 | 171,673 | - |
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)